Tucatinib approval by EMA expands options for HER2-positive locally advanced or metastatic breast cancer

ESMO Open. 2021 Apr;6(2):100063. doi: 10.1016/j.esmoop.2021.100063. Epub 2021 Mar 3.

Authors

C Corti¹, C Criscitiello²

Affiliations

¹ Department of Oncology and Haematology (DIPO), University of Milan, Milan, Italy; Division of Early Drug Development for Innovative Therapy, European Institute of Oncology, IRCCS, Milan, Italy.
² Department of Oncology and Haematology (DIPO), University of Milan, Milan, Italy; Division of Early Drug Development for Innovative Therapy, European Institute of Oncology, IRCCS, Milan, Italy. Electronic address: carmen.criscitiello@ieo.it.

No abstract available

Publication types

Editorial

MeSH terms

Breast Neoplasms* / drug therapy
Erb-b2 Receptor Tyrosine Kinases / genetics
Female
Humans
Oxazoles
Pyridines
Quinazolines

Substances

Oxazoles
Pyridines
Quinazolines
Erb-b2 Receptor Tyrosine Kinases
tucatinib